Drugs / MVA NP+M1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02014168 | Jan → Apr 2014 | influenza | University of Oxford | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA NP+M1 | “The MVA NP+M1 vaccine has been evaluated in five previous clinical trials.” NCT02014168 ↗ |
| Modality | Vaccine | “The second will be an investigational viral vectored vaccine called MVA NP+M1.” NCT02014168 ↗ |
| Route | Intramuscular | “1 dose (0.5ml) of Viroflu® and 1 dose of 1.5 x10\^8 pfu MVA-NP+M1 intramuscularly into the vastus lateralis muscle on day 0.” NCT02014168 ↗ |